|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0010453,
umls-concept:C0034833,
umls-concept:C0042133,
umls-concept:C0086418,
umls-concept:C0162638,
umls-concept:C0205263,
umls-concept:C0205314,
umls-concept:C0332197,
umls-concept:C0521387,
umls-concept:C0679622,
umls-concept:C1280500,
umls-concept:C1455381,
umls-concept:C1514485,
umls-concept:C1709060
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-4-7
|
|
pubmed:abstractText |
Asoprisnil, a selective progesterone (P4) receptor (PR) modulator (SPRM) with mixed P4 agonist/antagonist activities, reduces uterine leiomyoma volume in a dose-dependent manner in the presence of follicular phase estrogen concentrations. The evidence from clinical studies suggests that asoprisnil may directly target the uterine leiomyomata.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CASP3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Caspases,
http://linkedlifedata.com/resource/pubmed/chemical/Estrenes,
http://linkedlifedata.com/resource/pubmed/chemical/Oximes,
http://linkedlifedata.com/resource/pubmed/chemical/Poly(ADP-ribose) Polymerases,
http://linkedlifedata.com/resource/pubmed/chemical/Proliferating Cell Nuclear Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/asoprisnil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0021-972X
|
|
pubmed:author |
pubmed-author:ChenWeiW,
pubmed-author:ChwaliszKristofK,
pubmed-author:DemannoDeborah ADA,
pubmed-author:DeyD KDK,
pubmed-author:LuT NTN,
pubmed-author:MaruoTakeshiT,
pubmed-author:MorikawaAkiraA,
pubmed-author:OharaNoriyukiN,
pubmed-author:SasakiHirokoH,
pubmed-author:WangJiayinJ,
pubmed-author:YoshidaShigekiS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1296-304
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16464945-Apoptosis,
pubmed-meshheading:16464945-Blotting, Western,
pubmed-meshheading:16464945-Caspase 3,
pubmed-meshheading:16464945-Caspases,
pubmed-meshheading:16464945-Cell Proliferation,
pubmed-meshheading:16464945-Cells, Cultured,
pubmed-meshheading:16464945-Dose-Response Relationship, Drug,
pubmed-meshheading:16464945-Estrenes,
pubmed-meshheading:16464945-Female,
pubmed-meshheading:16464945-Genes, bcl-2,
pubmed-meshheading:16464945-Humans,
pubmed-meshheading:16464945-In Situ Nick-End Labeling,
pubmed-meshheading:16464945-Leiomyoma,
pubmed-meshheading:16464945-Myometrium,
pubmed-meshheading:16464945-Oximes,
pubmed-meshheading:16464945-Poly(ADP-ribose) Polymerases,
pubmed-meshheading:16464945-Proliferating Cell Nuclear Antigen,
pubmed-meshheading:16464945-Receptors, Progesterone,
pubmed-meshheading:16464945-Uterine Neoplasms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe 650-0017, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
